



8EHQ-0802-15179

MR 60957

RECEIVED
OPPT CBICThe Dow Chemical Company
Midland, Michigan 486741803 BUILDING 2002 AUG -6 AM 11:14
July 30, 2002CERTIFIED MAIL--RETURN RECEIPT REQUESTED
7000 1530 0005 1754 9483

CONTAINS NO CONFIDENTIAL BUSINESS INFORMATION

Document Processing Center (TS-790)
Office of Toxic Substances
U.S. Environmental Protection Agency
Ariel Rios Building
1200 Pennsylvania Avenue NW
Washington, DC 20460
Attn: 8(e) Coordinator

Contain NO CBI

Re: Propane, 1-Nitro
CASRN: 108-03-2



8EHQ-02-15179

Dear Sir/Madam:

The following information is being submitted by The Dow Chemical Company (Dow) pursuant to current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act. Dow has made no determination as to whether a significant risk of injury to health or the environment is actually presented by the findings.

Male and female CD (SD)BR rats were administered the test substance at 0, 10, 50 and 90 mg/kg/day by oral gavage in a 28-day Repeated Dose Toxicity Study with Reproduction/Developmental Toxicity Screening Test.

During the first week of treatment, decreased activity, decreased reactivity to stimuli, decreased responsiveness to touch, enlarged or protruding eyes, eye lids partially closed, incoordinated gait, dragging hindquarters, knuckling of the limbs, perioral soiling (salivation), and clear periocular soiling were observed in male rats administered 90 mg/kg/day. Two males in this group were sacrificed in moribund condition, and decreased feed consumption and body weight loss occurred in the remaining male rats at this dose level. No adverse clinical effects were noted in female rats at this dose level; however, the females consumed 35% less feed than controls and experienced a net body weight loss during this period.



88020000165

2002 AUG 29 AM 10:07

RECEIVED
OPPT CBIC

U.S. Environmental Protection Agency
July 30, 2002
Page 2

In male rats administered 50 mg/kg/day, decreased reactivity to stimuli, incoordinated gait and clear perioral soiling were noted. These clinical signs were also accompanied by decreases in feed consumption and body weights.

No adverse effects were noted in female rats at the 50 mg/kg/day dose level nor in any animals in the 10 mg/kg/day group.

No written report of these results is yet available.

Sincerely,

A handwritten signature in cursive script, reading "Linda C. Burgert".

Linda C. Burgert
PH: 989-636-1011
FAX: 989-638-9933
E-MAIL: lburgert@dow.com

jt